Stifel Reiterates Hold Rating on Travere Therapeutics (TVTX)

Stifel analyst Alex Thompson reiterated a Hold rating on Travere Therapeutics (NASDAQ: TVTX).

The analyst commented, "Sparsentan sNDA acceptance in FSGS via standard review (PDUFA 1/13/26) and expectation for adcom represents a mixed outcome for the stock. Heading into the acceptance, management had conveyed an expectation for priority review and a potential launch in 2025. While we agree that acceptance represents an important step forward toward eventual approval, pushing out the timeline to next year represents a disappointment given street expectations for a rapid, narrative-shifting launch beginning later this year. Additionally, an adcom (if ultimately held) will be interesting and is not all that surprising given the precedent-setting nature of a Sparsentan approval in FSGS based largely on proteinuria findings vs. eGFR-- with potential broader implications for the nephrology development landscape. While this is supported by the PARASOL findings discussed last fall, we think a specific discussion of the Sparsentan data in FSGS will be informative."

For an analyst ratings summary and ratings history on Travere Therapeutics click here. For more ratings news on Travere Therapeutics click here.

Shares of Travere Therapeutics closed at $21.15 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Critical One Energy closes second tranche of flow-through placement